Atossa Genetics Announces FDA Approval of Endoxifen for "Expanded Access" as Preoperative Systemic Endocrine Therapy for a U.S. Breast Cancer Patient
Stock Information for Atossa Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.